Investing.comCodex · 实盘不做把握 5/10不做原因:风险收益比不佳
北京时间·🕒 发布 21:04:37·⟳ 抓取 21:05:42 +1m05s·⚡ 决策 08-27 22:10:22 +1h04m·61.1 天前
Celularity宣布与MuseCell建立Dezawa MuseCells美国制造合作，远期潜在采购额超3亿美元
事件方向为正，但当前披露是制造能力建设和远期潜在采购估计，不是确定订单；CELU.US已大幅盘中重定价且存在Nasdaq迟交10-Q不合规背景，追入的风险回报不合格。
📄 原文Investing.com↗ 原文
Celularity to manufacture Dezawa MuseCells for MuseCell Innovations
Nvidia shares rise as strong AI demand powers bumper earnings, bullish outlook FLORHAM PARK, N.J. & SINGAPORE - Celular…
不做 Celularity Inc.（CELU.US）
不追Celularity Inc.（CELU.US）：制造合作方向正面且名义五年潜在采购额很大，但不是确定订单，产品未获FDA批准；股价已盘中涨31.75%并从盘前高点回落，叠加迟交10-Q不合规背景，当前风险回报不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
这条消息给Celularity带来第三方细胞治疗制造收入期权，若按3亿美元五年潜在采购、年化约6000万美元，相对公司2025年现金6.2百万美元和约2900万股股本形成名义弹性；但文本明确该金额来自扩展关系估计、反映初始项目之外的未来项目，且相关产品未获FDA批准。CELU.US在美股盘中已涨31.75%，盘前最高到1.40美元后回落至1.1599美元，叠加前一日9.94%上涨和刚收到Nasdaq迟交10-Q不合规通知，短线边际edge不足，选择不追。
消息传播链
- Investing.com转载/编辑发布Celularity与MuseCell制造合作内容，未在本轮命中更早公司IR原文。市场反应:CELU.US截至2026-08-27 10:06:49 ET报1.1599美元，较前收涨31.75%。
- 2026-08-27 10:06 ET市场反应Futu非一手行情工具显示CELU.US处于美股连续交易，报价当前、未停牌，盘前曾到1.40美元后回落。市场反应:现价1.1599美元，买一1.16、卖一1.17，日内成交额约2579万美元。
关键理由
- 制造合作本身正向：Celularity可利用Florham Park cGMP-ready设施承接Dezawa MuseCells及衍生产品生产。
- 量级句：公告给出的潜在扩展采购额为五年超3亿美元，粗略年化约6000万美元；相对2025年10-K披露的现金6.2百万美元和2026年4月约2894.6万股股本，名义弹性很大，但不是已签最低采购承诺。
- 历史对齐样本显示CELU类似许可/合作公告首日可涨，但3至5日转负，追高后续胜率薄。
主要风险
- 公告明确金额是基于预测的潜在未来项目，未披露最低采购、毛利、付款时间或监管商业化路径，业绩兑现不确定。
- CELU.US已盘中上涨31.75%，盘前冲至1.40美元后回落，且公司前一日已有9.94%涨幅和Nasdaq迟交10-Q不合规背景，追高易高开低走。
反向证据
- 做多前查反向 · 来源 search_processed_events · 日期 2026-08-26 · 影响 weakens
已处理库显示Celularity因未提交2026年一季报和二季报10-Q收到Nasdaq不合规通知，需在2026-09-04前提交合规计划。
检索:CELU Nasdaq delayed 10-Q non-compliance 2026 - 做多前查反向 · 来源 kb_search · 日期 2026-04-30 · 影响 weakens
内部KB命中10-K披露现金6.2百万美元、累计亏损991.5百万美元等财务压力；未命中本次合作的确定订单条款。
检索:Celularity MuseCell Innovations Dezawa MuseCells 300 million manufacturing collaboration revenue cash risk 原文 ↗ - 做多前查反向 · 来源 stock_quote · 日期 2026-08-27 · 影响 weakens
CELU.US当前涨31.75%，20日涨31.38%，前一日涨9.94%，盘前高点1.40美元后回落至1.1599美元，显示事件已被强烈重定价。
检索:CELU.US stock_quote full
先例如何影响了这次决策
对本次决策的影响:先例确认事件方向偏正，但把执行从追涨ENTER压成AVOID，核心原因是当前涨幅已显著透支高相似样本。
方向:先例支持首日正反应，但高相似样本只有1条，且CELU自身同类合作公告3日和5日转负。
涨幅量级:唯一高相似对齐样本首日约+4.9%、3日-4.2%、5日-6.4%；当前已涨31.75%，明显超过可用对齐样本的保守幅度。
形态:CELU自身样本表现为首日反应后回吐；BJDX虽暴涨但属于低相似极端微盘样本，不适合定本次止盈止损。
历史先例(按相似度)
- 相似度 8/10 CELU.US 2026-03-10 Celularity宣布最高3500万美元战略许可交易并保留制造权。 原文 ↗
事件后 +1日 +4.9% · +2日 -3.4% · +3日 -4.2% · +4日 -7.9% · +5日 -6.4%
⚠未核对目标相位 — 该行涨幅别用来定止盈止损
相似度依据:同一标的、同属小盘再生医学公司许可/商业化合作，均有远期金额但兑现路径不确定。
经验:CELU同类合作公告首日可冲高，但3至5日收益转负，追高窗口很窄。 - 相似度 6/10 BJDX.US 2026-06-02 Bluejay Diagnostics与Argonaut宣布美国制造战略合作。 原文 ↗
事件后 +1日 +100.0% · +2日 +107.8% · +3日 +144.2% · +4日 +121.2% · +5日 +141.0%
相似度依据:同为小盘医疗制造战略合作，但并非细胞治疗且交易结构不同。
经验:极小盘医疗制造合作可触发暴涨，但波动极端，不能外推为CELU追高胜率。
工具调用 · 历史记录,结果未知(9 种)
- fetch_decision_experience · 结果未知
- search_processed_events · 结果未知
- search_case_library · 结果未知
- kb_fetch_document · 结果未知
- direct_instrument_candidates · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
- supply_chain_lookup · 结果未知
- event_study · 结果未知
原文全文
展开原文 · 2,316 字
Nvidia shares rise as strong AI demand powers bumper earnings, bullish outlook
FLORHAM PARK, N.J. & SINGAPORE - Celularity Inc. (NASDAQ:CELU) announced today a manufacturing collaboration with MuseCell Innovations Pte. Ltd. to establish U.S. production of Dezawa MuseCells at its Florham Park, New Jersey facility.
The initial program will establish manufacturing capability for Dezawa MuseCells from qualified perinatal sources using the licensed Dezawa Method. The collaboration also includes manufacturing of products derived from Dezawa MuseCells, including Dezawa MuseExosomes and Dezawa MuseSecretome, according to a press release statement.
MuseCell Innovations estimates that an expanded relationship could result in more than $300 million in aggregate purchases from Celularity over the next five years, based on current market conditions and projections for the Dezawa MuseCell platform. The estimate reflects potential future programs beyond the initial project.
Celularity operates a 147,215-square-foot facility in Florham Park that includes a cGMP-ready manufacturing center with nine Grade C/ISO 7 and six Grade D/ISO 8 manufacturing suites designed for commercial production of cellular therapies. The expanded collaboration is anticipated to generate more than 200 employment opportunities at the Florham Park site, spanning positions in biomanufacturing, quality control, engineering and support functions.
"Cellular medicine remains at the center of Celularity’s strategy, including our continued advancement of our proprietary placental-derived technologies," said Robert J. Hariri, Founder, Chairman and Chief Executive Officer of Celularity. "Our collaboration with MCI demonstrates how the manufacturing infrastructure and cellular expertise we have built can also support innovative third-party technologies."
Dezawa MuseCells are a naturally occurring cell population discovered by Professor Mari Dezawa. The biology and investigational applications have been described in more than 170 peer-reviewed publications and evaluated in multiple human clinical studies.
Neither cenplacel-L nor any MuseCell Innovations product has been approved by the U.S. Food and Drug Administration.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
FLORHAM PARK, N.J. & SINGAPORE - Celularity Inc. (NASDAQ:CELU) announced today a manufacturing collaboration with MuseCell Innovations Pte. Ltd. to establish U.S. production of Dezawa MuseCells at its Florham Park, New Jersey facility.
The initial program will establish manufacturing capability for Dezawa MuseCells from qualified perinatal sources using the licensed Dezawa Method. The collaboration also includes manufacturing of products derived from Dezawa MuseCells, including Dezawa MuseExosomes and Dezawa MuseSecretome, according to a press release statement.
MuseCell Innovations estimates that an expanded relationship could result in more than $300 million in aggregate purchases from Celularity over the next five years, based on current market conditions and projections for the Dezawa MuseCell platform. The estimate reflects potential future programs beyond the initial project.
Celularity operates a 147,215-square-foot facility in Florham Park that includes a cGMP-ready manufacturing center with nine Grade C/ISO 7 and six Grade D/ISO 8 manufacturing suites designed for commercial production of cellular therapies. The expanded collaboration is anticipated to generate more than 200 employment opportunities at the Florham Park site, spanning positions in biomanufacturing, quality control, engineering and support functions.
"Cellular medicine remains at the center of Celularity’s strategy, including our continued advancement of our proprietary placental-derived technologies," said Robert J. Hariri, Founder, Chairman and Chief Executive Officer of Celularity. "Our collaboration with MCI demonstrates how the manufacturing infrastructure and cellular expertise we have built can also support innovative third-party technologies."
Dezawa MuseCells are a naturally occurring cell population discovered by Professor Mari Dezawa. The biology and investigational applications have been described in more than 170 peer-reviewed publications and evaluated in multiple human clinical studies.
Neither cenplacel-L nor any MuseCell Innovations product has been approved by the U.S. Food and Drug Administration.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。